PMID- 19302801
OWN - NLM
STAT- MEDLINE
DCOM- 20090504
LR  - 20211020
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 84
IP  - 17-18
DP  - 2009 Apr 24
TI  - Differential behavioral and neurochemical effects of exercise, reboxetine and 
      citalopram with the forced swim test.
PG  - 584-9
LID - 10.1016/j.lfs.2009.02.005 [doi]
AB  - AIMS: In this study, we investigated whether short-term exercise, known to 
      promote hippocampal brain-derived neurotrophic factor (BDNF) expression, would 
      also enhance activity in the Porsolt forced swim test (FST), a model for 
      assessing antidepressant efficacy. We also wished to determine whether exercise 
      combined with antidepressants would be more effective at modifying behavior in 
      the FST than either intervention alone. In parallel with this, we also expected 
      that these interventions would preserve post-stress levels of BDNF, and that 
      antidepressants designed to selectively enhance noradrenergic or serotonergic 
      neurotransmission (reboxetine or citalopram, respectively) would have 
      differential effects on behavior and BDNF expression. MAIN METHODS: Male 
      Sprague-Dawley rats were treated with exercise (voluntary wheel running), 
      reboxetine, citalopram, or the combination of exercise and each antidepressant, 
      for 1 week. At the end of this period, a subset of animals from each treatment 
      group underwent the FST. Post-stress levels of hippocampal BDNF mRNA were then 
      quantified via in situ hybridization. KEY FINDINGS: Our results indicate that 
      while both exercise and antidepressant treatment preserved post-stress levels of 
      hippocampal BDNF mRNA, each intervention led to a unique behavioral profile in 
      the FST. We found that antidepressant treatment increased swimming time in the 
      FST, but that exercise decreased swimming time. While the combination of 
      reboxetine-plus-exercise led to an increase in climbing and diving, 
      citalopram-plus-exercise reduced these behaviors. SIGNIFICANCE: It is possible 
      that active behaviors during the FST, though specific to antidepressant 
      medications, may not reflect increased hippocampal BDNF expression or other 
      survival- associated benefits.
FAU - Arunrut, Teda
AU  - Arunrut T
AD  - Department of Biological Sciences, California State University, Los Angeles, 5151 
      State University Drive, Los Angeles, CA 90032, United States.
FAU - Alejandre, Hilda
AU  - Alejandre H
FAU - Chen, Michael
AU  - Chen M
FAU - Cha, Joseph
AU  - Cha J
FAU - Russo-Neustadt, Amelia
AU  - Russo-Neustadt A
LA  - eng
GR  - R01 MH059776/MH/NIMH NIH HHS/United States
GR  - R01 MH059776-11/MH/NIMH NIH HHS/United States
GR  - MH59776/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20090212
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Morpholines)
RN  - 0 (RNA, Messenger)
RN  - 0DHU5B8D6V (Citalopram)
RN  - 947S0YZ36I (Reboxetine)
SB  - IM
MH  - Animals
MH  - Antidepressive Agents, Second-Generation/*pharmacology
MH  - Behavior, Animal/*drug effects
MH  - Brain-Derived Neurotrophic Factor/genetics
MH  - Citalopram/*pharmacology
MH  - In Situ Hybridization
MH  - Male
MH  - Morpholines/*pharmacology
MH  - RNA, Messenger/genetics
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reboxetine
MH  - *Swimming
PMC - PMC2668951
MID - NIHMS98172
EDAT- 2009/03/24 09:00
MHDA- 2009/05/05 09:00
PMCR- 2010/04/24
CRDT- 2009/03/24 09:00
PHST- 2008/07/15 00:00 [received]
PHST- 2009/01/20 00:00 [revised]
PHST- 2009/02/03 00:00 [accepted]
PHST- 2009/03/24 09:00 [entrez]
PHST- 2009/03/24 09:00 [pubmed]
PHST- 2009/05/05 09:00 [medline]
PHST- 2010/04/24 00:00 [pmc-release]
AID - S0024-3205(09)00068-X [pii]
AID - 10.1016/j.lfs.2009.02.005 [doi]
PST - ppublish
SO  - Life Sci. 2009 Apr 24;84(17-18):584-9. doi: 10.1016/j.lfs.2009.02.005. Epub 2009 
      Feb 12.